Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Novartis
US Department of Justice
Medtronic
Fuji
McKinsey
Federal Trade Commission
Deloitte
Baxter
Queensland Health

Generated: October 23, 2017

DrugPatentWatch Database Preview

ULORIC Drug Profile

« Back to Dashboard

What is the patent landscape for Uloric, and when can generic versions of Uloric launch?

Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and three patent family members in thirty-five countries and thirteen supplementary protection certificates in ten countries.

The generic ingredient in ULORIC is febuxostat. There are twenty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the febuxostat profile page.

Summary for Tradename: ULORIC

US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list85
Clinical Trials: see list26
Patent Applications: see list195
Drug Prices:see details
DailyMed Link:ULORIC at DailyMed

Pharmacology for Tradename: ULORIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ULORIC

Drugname Dosage Strength RLD Submissiondate
febuxostatTablets40 mg and 80 mgUloric2/13/2013

International Patent Family for Tradename: ULORIC

Country Document Number Estimated Expiration
India191537► Subscribe
Poland200710► Subscribe
Norway321308► Subscribe
European Patent Office0513379► Subscribe
World Intellectual Property Organization (WIPO)03082279► Subscribe
Bulgaria104159► Subscribe
Germany69122084► Subscribe
South Korea20130097775► Subscribe
Czech Republic298170► Subscribe
China1275126► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ULORIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/019United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023.
2010 00015Denmark► Subscribe
5Finland► Subscribe
/2010Austria► SubscribePRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
C015/2010Ireland► SubscribeSPC015/2010: 20101001, EXPIRES: 20230420
0140037 00152Estonia► SubscribePRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008
682Luxembourg► Subscribe91682, EXPIRES: 20230421
00447Netherlands► SubscribePRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2010 00015Denmark► SubscribePRODUCT NAME: FEBUXOSTAT; REG. NO/DATE: EU/1/08/447/001-004 20080421
2010005,C1020454Lithuania► SubscribePRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004, 0080421
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Colorcon
Healthtrust
AstraZeneca
Farmers Insurance
Fuji
Cipla
Merck
Citi
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot